Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

You may be eligible if

• HIV-infected children participating in individual prospective paediatric HIV cohorts
• Receive Atazanavir treatment during 01JAN2011 to 30DEC2013
• Age \<18 years old on the date starting an Atazanavir-containing regimen
• Have a minimum of 3 months of follow-up